News | April 23, 2026
AbbVie bets $1.4B on North Carolina pharma mega-campus
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Highlights Mirvetuximab-based regimen promise
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
This study evaluated a difficult-to-treat Crohn's disease patient population
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Improvements were also seen in complete response rates, duration of response, and time to next treatment
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
